Related Experiment Videos
Regulation of PAI-1 concentration in platelets by systemic administration of antisense oligonucleotides to rats
Z Pawlowska1, E Chabielska, A Kobylanska
1Department of Biophysics, Medical University in Lodz, Poland.
Abstract:
In this report we tested the effect of oligodeoxyribonucleotides antisense to PAI-1 mRNA administered into rats on PAI-1 concentration in platelets. Low doses of the antisense oligonucleotide (MPO-16R) reduced PAI-1 activity, both in rat blood plasma and platelet lysates by 20.5% and 28.7%, respectively. There was no change in platelet count after treatment with MPO-16R but treated platelets showed lower aggregability as compared with controls (37 +/- 13% and 54 +/- 12%, respectively). In an experimental model of rat arterial thrombosis, low doses of MPO-16R caused a significant delay in the occlusion time (31.8%). These data further support for the role of PAI-1 as a major determinant of arterial thrombolysis resistance and for the first time demonstrate the possibility of reduction of platelet PAI-1 concentration by antisense approach.
Insights
Antisense oligodeoxynucleotides targeting plasminogen activator inhibitor-1 (PAI-1) mRNA reduced PAI-1 levels and platelet aggregation in rats. This approach offers a novel strategy for managing arterial thrombosis by targeting platelet PAI-1.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Plasminogen activator inhibitor-1 (PAI-1) plays a critical role in regulating fibrinolysis and is implicated in arterial thrombosis.
- Elevated PAI-1 levels are associated with increased thrombotic risk and resistance to thrombolysis.
- Targeting PAI-1 offers a potential therapeutic strategy for thrombotic disorders.
Purpose of the Study:
- To investigate the efficacy of antisense oligodeoxynucleotides targeting PAI-1 mRNA in reducing PAI-1 concentration in rat platelets.
- To evaluate the impact of antisense treatment on platelet function, including aggregability and thrombus formation in vivo.
Main Methods:
- Administration of low doses of MPO-16R, an antisense oligodeoxynucleotide to PAI-1 mRNA, into rats.
- Measurement of PAI-1 activity in rat blood plasma and platelet lysates.
- Assessment of platelet count and platelet aggregability.
- Evaluation of arterial thrombosis in an experimental rat model.
Main Results:
- Low-dose MPO-16R significantly reduced PAI-1 activity in both plasma (20.5%) and platelet lysates (28.7%).
- Platelet aggregability was significantly decreased in MPO-16R treated rats compared to controls (37% vs. 54%).
- A significant delay in arterial occlusion time (31.8%) was observed in rats treated with MPO-16R, indicating reduced thrombus formation.
Conclusions:
- Antisense oligodeoxynucleotides can effectively reduce platelet PAI-1 concentration and activity.
- Targeting PAI-1 with antisense therapy demonstrates potential in mitigating platelet hyperaggregability and arterial thrombosis.
- This study provides the first evidence for the successful reduction of platelet PAI-1 via an antisense approach, supporting its role in thrombosis therapy.